{"transactions":[{"id":924470,"issuer":{"id":4069,"kind":"organization","name":"IDEAYA Biosciences, Inc.","symbol":"IDYA"},"owners":[{"id":68161,"kind":"person","name":"Snyder Douglas B.","position":1,"cik":"0001754125","reported_name":"Snyder Douglas B.","relationship":{"officer":true,"officer_title":"SVP, General Counsel"}}],"security":"Stock Option (right to buy)","published_at":"2026-02-03T00:57:16.000Z","date":"2026-01-30","kind":"grant","planned":false,"acquired":true,"shares":130000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"25% of the shares subject to the option vest on the first anniversary measured from January 1, 2026 (the \"Vesting Commencement Date\"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date."}],"balance_after":130000,"derivative":{"exercise_price":32.19,"expiration_date":"2036-01-30","underlying":"Common Stock","underlying_shares":130000},"source":{"system":"sec-edgar","filing":"0001610717-26-000033","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1676725/000161071726000033/form4.xml","form_type":"4"}},{"id":924469,"issuer":{"id":4069,"kind":"organization","name":"IDEAYA Biosciences, Inc.","symbol":"IDYA"},"owners":[{"id":68161,"kind":"person","name":"Snyder Douglas B.","position":1,"cik":"0001754125","reported_name":"Snyder Douglas B.","relationship":{"officer":true,"officer_title":"SVP, General Counsel"}}],"security":"Common Stock","published_at":"2026-02-03T00:57:16.000Z","date":"2025-11-28","kind":"grant","planned":false,"acquired":true,"shares":1041,"price":16.9065,"value":17599.6665,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The shares were acquired under the Issuer's Employee Stock Purchase Plan in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c)."}],"balance_after":2080,"source":{"system":"sec-edgar","filing":"0001610717-26-000033","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1676725/000161071726000033/form4.xml","form_type":"4"}},{"id":924468,"issuer":{"id":4069,"kind":"organization","name":"IDEAYA Biosciences, Inc.","symbol":"IDYA"},"owners":[{"id":68161,"kind":"person","name":"Snyder Douglas B.","position":1,"cik":"0001754125","reported_name":"Snyder Douglas B.","relationship":{"officer":true,"officer_title":"SVP, General Counsel"}}],"security":"Common Stock","published_at":"2026-02-03T00:57:16.000Z","date":"2025-05-30","kind":"grant","planned":false,"acquired":true,"shares":1039,"price":16.9065,"value":17565.8535,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The shares were acquired under the Issuer's Employee Stock Purchase Plan in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c)."}],"balance_after":1039,"source":{"system":"sec-edgar","filing":"0001610717-26-000033","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1676725/000161071726000033/form4.xml","form_type":"4"}},{"id":1237856,"issuer":{"id":4069,"kind":"organization","name":"IDEAYA Biosciences, Inc.","symbol":"IDYA"},"owners":[{"id":68161,"kind":"person","name":"Snyder Douglas B.","position":1,"cik":"0001754125","reported_name":"Snyder Douglas B.","relationship":{"officer":true,"officer_title":"SVP, General Counsel"}}],"security":"Stock Option (right to buy)","published_at":"2025-02-28T23:00:54.000Z","date":"2025-02-27","kind":"grant","planned":false,"acquired":true,"shares":33000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of the shares subject to the option vest on the first anniversary measured from January 1, 2025 (the \"Vesting Commencement Date\"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date."}],"balance_after":33000,"derivative":{"exercise_price":20.24,"expiration_date":"2035-02-26","underlying":"Common Stock","underlying_shares":33000},"source":{"system":"sec-edgar","filing":"0001610717-25-000039","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1676725/000161071725000039/form4.xml","form_type":"4"}},{"id":1398340,"issuer":{"id":4069,"kind":"organization","name":"IDEAYA Biosciences, Inc.","symbol":"IDYA"},"owners":[{"id":68161,"kind":"person","name":"Snyder Douglas B.","position":1,"cik":"0001754125","reported_name":"Snyder Douglas B.","relationship":{"officer":true,"officer_title":"SVP, General Counsel"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-09-27T20:25:26.000Z","date":"2024-09-26","kind":"grant","planned":false,"acquired":true,"shares":140000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of the shares subject to the option vest on the first anniversary measured from September 18, 2024 (the \"Vesting Commencement Date\"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date."}],"balance_after":140000,"derivative":{"exercise_price":30.5,"expiration_date":"2034-09-25","underlying":"Common Stock","underlying_shares":140000},"source":{"system":"sec-edgar","filing":"0001610717-24-000497","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1676725/000161071724000497/form4.xml","form_type":"4"}},{"id":2722886,"issuer":{"id":139616,"kind":"organization","name":"GW PHARMACEUTICALS PLC","symbol":"GWPH"},"owners":[{"id":68161,"kind":"person","name":"Snyder Douglas B.","position":1,"cik":"0001754125","reported_name":"Snyder Douglas B.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Share Options","published_at":"2021-05-07T16:15:52.000Z","date":"2021-05-05","kind":"disposition_to_issuer","acquired":false,"shares":72528,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the Transaction Agreement, one-third of these share options vested and were canceled in connection with the closing of the transactions contemplated by the Transaction Agreement in exchange for an all-cash payment equal to the value of the share options based on the value of the transaction consideration, and the remaining two-thirds were converted into an option to acquire Jazz ordinary shares (with any performance goals deemed fully satisfied), half of which will vest on March 2, 2022 and half of which will vest on March 2, 2023."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Pursuant to the Transaction Agreement, one-third of these share options vested and were canceled in connection with the closing of the transactions contemplated by the Transaction Agreement in exchange for an all-cash payment equal to the value of the share options based on the value of the transaction consideration, and the remaining two-thirds were converted into an option to acquire Jazz ordinary shares (with any performance goals deemed fully satisfied), half of which will vest on March 2, 2022 and half of which will vest on March 2, 2023."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"These stock options were granted with automatic vesting on exercisable date."}],"balance_after":0,"derivative":{"exercise_price":0.0017,"underlying":"Ordinary Shares","underlying_shares":72528},"source":{"system":"sec-edgar","filing":"0000899243-21-018666","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1351288/000089924321018666/doc4.xml","form_type":"4"}},{"id":2722885,"issuer":{"id":139616,"kind":"organization","name":"GW PHARMACEUTICALS PLC","symbol":"GWPH"},"owners":[{"id":68161,"kind":"person","name":"Snyder Douglas B.","position":1,"cik":"0001754125","reported_name":"Snyder Douglas B.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Share Options","published_at":"2021-05-07T16:15:52.000Z","date":"2021-05-05","kind":"disposition_to_issuer","acquired":false,"shares":45360,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the Transaction Agreement, one-third of these share options vested and were canceled in connection with the closing of the transactions contemplated by the Transaction Agreement in exchange for an all-cash payment equal to the value of the share options based on the value of the transaction consideration, and the remaining two-thirds were converted into an option to acquire Jazz ordinary shares (with any performance goals deemed fully satisfied), half of which will vest on March 2, 2022 and half of which will vest on March 2, 2023."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Pursuant to the Transaction Agreement, one-third of these share options vested and were canceled in connection with the closing of the transactions contemplated by the Transaction Agreement in exchange for an all-cash payment equal to the value of the share options based on the value of the transaction consideration, and the remaining two-thirds were converted into an option to acquire Jazz ordinary shares (with any performance goals deemed fully satisfied), half of which will vest on March 2, 2022 and half of which will vest on March 2, 2023."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"These stock options were granted with automatic vesting on exercisable date."}],"balance_after":0,"derivative":{"exercise_price":0.0017,"underlying":"Ordinary Shares","underlying_shares":45360},"source":{"system":"sec-edgar","filing":"0000899243-21-018666","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1351288/000089924321018666/doc4.xml","form_type":"4"}},{"id":2722884,"issuer":{"id":139616,"kind":"organization","name":"GW PHARMACEUTICALS PLC","symbol":"GWPH"},"owners":[{"id":68161,"kind":"person","name":"Snyder Douglas B.","position":1,"cik":"0001754125","reported_name":"Snyder Douglas B.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Share Options","published_at":"2021-05-07T16:15:52.000Z","date":"2021-05-05","kind":"disposition_to_issuer","acquired":false,"shares":89952,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the Transaction Agreement, dated as of February 3, 2021 (the \"Transaction Agreement\"), by and among the Company, Jazz and Bidco, these share options vested (to the extent unvested) and were canceled in connection with the closing of the transactions contemplated by the Transaction Agreement in exchange for an all-cash payment equal to the value of the share options based on the value of the transaction consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Pursuant to the Transaction Agreement, dated as of February 3, 2021 (the \"Transaction Agreement\"), by and among the Company, Jazz and Bidco, these share options vested (to the extent unvested) and were canceled in connection with the closing of the transactions contemplated by the Transaction Agreement in exchange for an all-cash payment equal to the value of the share options based on the value of the transaction consideration."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"These stock options were granted with automatic vesting on exercisable date."}],"balance_after":0,"derivative":{"exercise_price":0.0017,"underlying":"Ordinary Shares","underlying_shares":89952},"source":{"system":"sec-edgar","filing":"0000899243-21-018666","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1351288/000089924321018666/doc4.xml","form_type":"4"}},{"id":2722883,"issuer":{"id":139616,"kind":"organization","name":"GW PHARMACEUTICALS PLC","symbol":"GWPH"},"owners":[{"id":68161,"kind":"person","name":"Snyder Douglas B.","position":1,"cik":"0001754125","reported_name":"Snyder Douglas B.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Share Options","published_at":"2021-05-07T16:15:52.000Z","date":"2021-05-05","kind":"disposition_to_issuer","acquired":false,"shares":149856,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the Transaction Agreement, dated as of February 3, 2021 (the \"Transaction Agreement\"), by and among the Company, Jazz and Bidco, these share options vested (to the extent unvested) and were canceled in connection with the closing of the transactions contemplated by the Transaction Agreement in exchange for an all-cash payment equal to the value of the share options based on the value of the transaction consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Pursuant to the Transaction Agreement, dated as of February 3, 2021 (the \"Transaction Agreement\"), by and among the Company, Jazz and Bidco, these share options vested (to the extent unvested) and were canceled in connection with the closing of the transactions contemplated by the Transaction Agreement in exchange for an all-cash payment equal to the value of the share options based on the value of the transaction consideration."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"These stock options were granted with automatic vesting on exercisable date."}],"balance_after":0,"derivative":{"exercise_price":0.0017,"underlying":"Ordinary Shares","underlying_shares":149856},"source":{"system":"sec-edgar","filing":"0000899243-21-018666","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1351288/000089924321018666/doc4.xml","form_type":"4"}},{"id":2722882,"issuer":{"id":139616,"kind":"organization","name":"GW PHARMACEUTICALS PLC","symbol":"GWPH"},"owners":[{"id":68161,"kind":"person","name":"Snyder Douglas B.","position":1,"cik":"0001754125","reported_name":"Snyder Douglas B.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Share Options","published_at":"2021-05-07T16:15:52.000Z","date":"2021-05-05","kind":"disposition_to_issuer","acquired":false,"shares":13272,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the Transaction Agreement, dated as of February 3, 2021 (the \"Transaction Agreement\"), by and among the Company, Jazz and Bidco, these share options vested (to the extent unvested) and were canceled in connection with the closing of the transactions contemplated by the Transaction Agreement in exchange for an all-cash payment equal to the value of the share options based on the value of the transaction consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Pursuant to the Transaction Agreement, dated as of February 3, 2021 (the \"Transaction Agreement\"), by and among the Company, Jazz and Bidco, these share options vested (to the extent unvested) and were canceled in connection with the closing of the transactions contemplated by the Transaction Agreement in exchange for an all-cash payment equal to the value of the share options based on the value of the transaction consideration."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"These stock options were granted with automatic vesting on exercisable date."}],"balance_after":0,"derivative":{"exercise_price":0.0017,"underlying":"Ordinary Shares","underlying_shares":13272},"source":{"system":"sec-edgar","filing":"0000899243-21-018666","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1351288/000089924321018666/doc4.xml","form_type":"4"}},{"id":2722881,"issuer":{"id":139616,"kind":"organization","name":"GW PHARMACEUTICALS PLC","symbol":"GWPH"},"owners":[{"id":68161,"kind":"person","name":"Snyder Douglas B.","position":1,"cik":"0001754125","reported_name":"Snyder Douglas B.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Share Options","published_at":"2021-05-07T16:15:52.000Z","date":"2021-05-05","kind":"disposition_to_issuer","acquired":false,"shares":88524,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the Transaction Agreement, dated as of February 3, 2021 (the \"Transaction Agreement\"), by and among the Company, Jazz and Bidco, these share options vested (to the extent unvested) and were canceled in connection with the closing of the transactions contemplated by the Transaction Agreement in exchange for an all-cash payment equal to the value of the share options based on the value of the transaction consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Pursuant to the Transaction Agreement, dated as of February 3, 2021 (the \"Transaction Agreement\"), by and among the Company, Jazz and Bidco, these share options vested (to the extent unvested) and were canceled in connection with the closing of the transactions contemplated by the Transaction Agreement in exchange for an all-cash payment equal to the value of the share options based on the value of the transaction consideration."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"These stock options were granted with automatic vesting on exercisable date."}],"balance_after":0,"derivative":{"exercise_price":0.0017,"underlying":"Ordinary Shares","underlying_shares":88524},"source":{"system":"sec-edgar","filing":"0000899243-21-018666","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1351288/000089924321018666/doc4.xml","form_type":"4"}},{"id":2722880,"issuer":{"id":139616,"kind":"organization","name":"GW PHARMACEUTICALS PLC","symbol":"GWPH"},"owners":[{"id":68161,"kind":"person","name":"Snyder Douglas B.","position":1,"cik":"0001754125","reported_name":"Snyder Douglas B.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Share Options","published_at":"2021-05-07T16:15:52.000Z","date":"2021-05-05","kind":"disposition_to_issuer","acquired":false,"shares":9612,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the Transaction Agreement, dated as of February 3, 2021 (the \"Transaction Agreement\"), by and among the Company, Jazz and Bidco, these share options vested (to the extent unvested) and were canceled in connection with the closing of the transactions contemplated by the Transaction Agreement in exchange for an all-cash payment equal to the value of the share options based on the value of the transaction consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Pursuant to the Transaction Agreement, dated as of February 3, 2021 (the \"Transaction Agreement\"), by and among the Company, Jazz and Bidco, these share options vested (to the extent unvested) and were canceled in connection with the closing of the transactions contemplated by the Transaction Agreement in exchange for an all-cash payment equal to the value of the share options based on the value of the transaction consideration."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"These stock options were granted with automatic vesting on exercisable date."}],"balance_after":0,"derivative":{"exercise_price":0.0017,"underlying":"Ordinary Shares","underlying_shares":9612},"source":{"system":"sec-edgar","filing":"0000899243-21-018666","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1351288/000089924321018666/doc4.xml","form_type":"4"}},{"id":2722879,"issuer":{"id":139616,"kind":"organization","name":"GW PHARMACEUTICALS PLC","symbol":"GWPH"},"owners":[{"id":68161,"kind":"person","name":"Snyder Douglas B.","position":1,"cik":"0001754125","reported_name":"Snyder Douglas B.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Share Options","published_at":"2021-05-07T16:15:52.000Z","date":"2021-05-05","kind":"disposition_to_issuer","acquired":false,"shares":9180,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the Transaction Agreement, dated as of February 3, 2021 (the \"Transaction Agreement\"), by and among the Company, Jazz and Bidco, these share options vested (to the extent unvested) and were canceled in connection with the closing of the transactions contemplated by the Transaction Agreement in exchange for an all-cash payment equal to the value of the share options based on the value of the transaction consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Pursuant to the Transaction Agreement, dated as of February 3, 2021 (the \"Transaction Agreement\"), by and among the Company, Jazz and Bidco, these share options vested (to the extent unvested) and were canceled in connection with the closing of the transactions contemplated by the Transaction Agreement in exchange for an all-cash payment equal to the value of the share options based on the value of the transaction consideration."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"These stock options were granted with automatic vesting on exercisable date."}],"balance_after":0,"derivative":{"exercise_price":0.0017,"underlying":"Ordinary Shares","underlying_shares":9180},"source":{"system":"sec-edgar","filing":"0000899243-21-018666","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1351288/000089924321018666/doc4.xml","form_type":"4"}},{"id":2722878,"issuer":{"id":139616,"kind":"organization","name":"GW PHARMACEUTICALS PLC","symbol":"GWPH"},"owners":[{"id":68161,"kind":"person","name":"Snyder Douglas B.","position":1,"cik":"0001754125","reported_name":"Snyder Douglas B.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Share Options","published_at":"2021-05-07T16:15:52.000Z","date":"2021-05-05","kind":"disposition_to_issuer","acquired":false,"shares":46644,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the Transaction Agreement, dated as of February 3, 2021 (the \"Transaction Agreement\"), by and among the Company, Jazz and Bidco, these share options vested (to the extent unvested) and were canceled in connection with the closing of the transactions contemplated by the Transaction Agreement in exchange for an all-cash payment equal to the value of the share options based on the value of the transaction consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Pursuant to the Transaction Agreement, dated as of February 3, 2021 (the \"Transaction Agreement\"), by and among the Company, Jazz and Bidco, these share options vested (to the extent unvested) and were canceled in connection with the closing of the transactions contemplated by the Transaction Agreement in exchange for an all-cash payment equal to the value of the share options based on the value of the transaction consideration."}],"balance_after":0,"derivative":{"exercise_price":14.3342,"expiration_date":"2029-03-01","underlying":"Ordinary Shares","underlying_shares":46644},"source":{"system":"sec-edgar","filing":"0000899243-21-018666","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1351288/000089924321018666/doc4.xml","form_type":"4"}},{"id":2722877,"issuer":{"id":139616,"kind":"organization","name":"GW PHARMACEUTICALS PLC","symbol":"GWPH"},"owners":[{"id":68161,"kind":"person","name":"Snyder Douglas B.","position":1,"cik":"0001754125","reported_name":"Snyder Douglas B.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Share Options","published_at":"2021-05-07T16:15:52.000Z","date":"2021-05-05","kind":"disposition_to_issuer","acquired":false,"shares":63252,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the Transaction Agreement, dated as of February 3, 2021 (the \"Transaction Agreement\"), by and among the Company, Jazz and Bidco, these share options vested (to the extent unvested) and were canceled in connection with the closing of the transactions contemplated by the Transaction Agreement in exchange for an all-cash payment equal to the value of the share options based on the value of the transaction consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Pursuant to the Transaction Agreement, dated as of February 3, 2021 (the \"Transaction Agreement\"), by and among the Company, Jazz and Bidco, these share options vested (to the extent unvested) and were canceled in connection with the closing of the transactions contemplated by the Transaction Agreement in exchange for an all-cash payment equal to the value of the share options based on the value of the transaction consideration."}],"balance_after":0,"derivative":{"exercise_price":9.6092,"expiration_date":"2028-02-26","underlying":"Ordinary Shares","underlying_shares":63252},"source":{"system":"sec-edgar","filing":"0000899243-21-018666","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1351288/000089924321018666/doc4.xml","form_type":"4"}},{"id":2722876,"issuer":{"id":139616,"kind":"organization","name":"GW PHARMACEUTICALS PLC","symbol":"GWPH"},"owners":[{"id":68161,"kind":"person","name":"Snyder Douglas B.","position":1,"cik":"0001754125","reported_name":"Snyder Douglas B.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Share Options","published_at":"2021-05-07T16:15:52.000Z","date":"2021-05-05","kind":"disposition_to_issuer","acquired":false,"shares":82956,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the Transaction Agreement, dated as of February 3, 2021 (the \"Transaction Agreement\"), by and among the Company, Jazz and Bidco, these share options vested (to the extent unvested) and were canceled in connection with the closing of the transactions contemplated by the Transaction Agreement in exchange for an all-cash payment equal to the value of the share options based on the value of the transaction consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Pursuant to the Transaction Agreement, dated as of February 3, 2021 (the \"Transaction Agreement\"), by and among the Company, Jazz and Bidco, these share options vested (to the extent unvested) and were canceled in connection with the closing of the transactions contemplated by the Transaction Agreement in exchange for an all-cash payment equal to the value of the share options based on the value of the transaction consideration."}],"balance_after":0,"derivative":{"exercise_price":8.3767,"expiration_date":"2027-08-10","underlying":"Ordinary Shares","underlying_shares":82956},"source":{"system":"sec-edgar","filing":"0000899243-21-018666","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1351288/000089924321018666/doc4.xml","form_type":"4"}},{"id":2722875,"issuer":{"id":139616,"kind":"organization","name":"GW PHARMACEUTICALS PLC","symbol":"GWPH"},"owners":[{"id":68161,"kind":"person","name":"Snyder Douglas B.","position":1,"cik":"0001754125","reported_name":"Snyder Douglas B.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Ordinary Shares","published_at":"2021-05-07T16:15:52.000Z","date":"2021-05-05","kind":"disposition_to_issuer","acquired":false,"shares":61848,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On May 5, 2021, Jazz Pharmaceuticals Public Limited Company, a public limited company incorporated in the Republic of Ireland (\"Jazz\"), Jazz Pharmaceuticals UK Holdings Limited, a private limited company incorporated in England and Wales and an indirect wholly owned subsidiary of Jazz (\"Bidco\") and the DR Nominee (as defined in the Transaction Agreement) acquired all outstanding ordinary shares, par value British Pound Sterling 0.001 per share, of GW Pharmaceuticals plc, a public limited company incorporated in England and Wales (the \"Company\"), by means of a scheme of arrangement under Part 26 of the UK Companies Act 2006 (the \"Scheme of Arrangement\") (continued in footnote 2)."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"At the effective time of the Scheme of Arrangement, Scheme Shareholders (as defined in the Scheme of Arrangement) became entitled to receive for each Scheme Share (as defined in the Scheme of Arrangement) held by them an amount equal to $16.66 2/3 in cash plus 0.010030 ordinary shares, nominal value $0.0001 per share, of Jazz (\"Jazz ordinary shares\"). The transaction is more fully described in the Company's definitive proxy statement filed with the Securities and Exchange Commission on March 15, 2021."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000899243-21-018666","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1351288/000089924321018666/doc4.xml","form_type":"4"}},{"id":2752836,"issuer":{"id":139616,"kind":"organization","name":"GW PHARMACEUTICALS PLC","symbol":"GWPH"},"owners":[{"id":68161,"kind":"person","name":"Snyder Douglas B.","position":1,"cik":"0001754125","reported_name":"Snyder Douglas B.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Ordinary Shares","published_at":"2021-04-08T20:00:09.000Z","date":"2021-03-26","kind":"sale","acquired":false,"shares":8400,"price":18.12,"value":152208.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represented by American Depositary Shares of the Issuer (\"ADS\"). Each ADS represents twelve ordinary shares of the Issuer."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a price per ordinary share converted from price per ADS."}],"balance_after":61848,"source":{"system":"sec-edgar","filing":"0000899243-21-015430","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1351288/000089924321015430/doc4.xml","form_type":"4"}},{"id":2808513,"issuer":{"id":139616,"kind":"organization","name":"GW PHARMACEUTICALS PLC","symbol":"GWPH"},"owners":[{"id":68161,"kind":"person","name":"Snyder Douglas B.","position":1,"cik":"0001754125","reported_name":"Snyder Douglas B.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Share Options","published_at":"2021-03-04T21:01:54.000Z","date":"2021-03-02","kind":"grant","acquired":true,"shares":45360,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F3","text":"Granted pursuant to the Issuer's Long-Term Incentive Plan."},{"field":"security","element":"securityTitle","label":"F6","text":"The share numbers underlying options granted on February 22, 2021 and reported on the reporting person's form 4 filed on February 24, 2021 were amended as of March 2, 2021 and as reported in this form 4."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Converted from British Pounds Sterling to U.S. Dollars using currency ratio of 1.00 British Pound Sterling = 1.41 U.S. Dollars as of February 22, 2021."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"These share options will vest in four equal annual installments beginning on February 22, 2022 and be automatically exercised upon vesting."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Subject to accelerated vesting in connection with the closing of the transactions contemplated by the Transaction Agreement, dated as of February 3, 2021, by and among Jazz Pharmaceuticals UK Holdings Limited, Jazz Pharmaceuticals Public Limited Company and GW Pharmaceuticals plc."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"These share options will vest in four equal annual installments beginning on February 22, 2022 and be automatically exercised upon vesting."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"Subject to accelerated vesting in connection with the closing of the transactions contemplated by the Transaction Agreement, dated as of February 3, 2021, by and among Jazz Pharmaceuticals UK Holdings Limited, Jazz Pharmaceuticals Public Limited Company and GW Pharmaceuticals plc."}],"balance_after":45360,"derivative":{"exercise_price":0.0014,"underlying":"Ordinary Shares","underlying_shares":45360},"source":{"system":"sec-edgar","filing":"0000899243-21-010018","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1351288/000089924321010018/doc4.xml","form_type":"4"}},{"id":2808512,"issuer":{"id":139616,"kind":"organization","name":"GW PHARMACEUTICALS PLC","symbol":"GWPH"},"owners":[{"id":68161,"kind":"person","name":"Snyder Douglas B.","position":1,"cik":"0001754125","reported_name":"Snyder Douglas B.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Share Options","published_at":"2021-03-04T21:01:54.000Z","date":"2021-03-02","kind":"grant","acquired":true,"shares":72258,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Granted pursuant to the Issuer's Long-Term Incentive Plan. These share options will vest and be automatically exercised on February 22, 2024 if certain performance conditions are satisfied."},{"field":"security","element":"securityTitle","label":"F6","text":"The share numbers underlying options granted on February 22, 2021 and reported on the reporting person's form 4 filed on February 24, 2021 were amended as of March 2, 2021 and as reported in this form 4."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Converted from British Pounds Sterling to U.S. Dollars using currency ratio of 1.00 British Pound Sterling = 1.41 U.S. Dollars as of February 22, 2021."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Granted pursuant to the Issuer's Long-Term Incentive Plan. These share options will vest and be automatically exercised on February 22, 2024 if certain performance conditions are satisfied."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Subject to accelerated vesting in connection with the closing of the transactions contemplated by the Transaction Agreement, dated as of February 3, 2021, by and among Jazz Pharmaceuticals UK Holdings Limited, Jazz Pharmaceuticals Public Limited Company and GW Pharmaceuticals plc."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Granted pursuant to the Issuer's Long-Term Incentive Plan. These share options will vest and be automatically exercised on February 22, 2024 if certain performance conditions are satisfied."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"Subject to accelerated vesting in connection with the closing of the transactions contemplated by the Transaction Agreement, dated as of February 3, 2021, by and among Jazz Pharmaceuticals UK Holdings Limited, Jazz Pharmaceuticals Public Limited Company and GW Pharmaceuticals plc."}],"balance_after":72258,"derivative":{"exercise_price":0.0014,"underlying":"Ordinary Shares","underlying_shares":72258},"source":{"system":"sec-edgar","filing":"0000899243-21-010018","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1351288/000089924321010018/doc4.xml","form_type":"4"}},{"id":2819584,"issuer":{"id":139616,"kind":"organization","name":"GW PHARMACEUTICALS PLC","symbol":"GWPH"},"owners":[{"id":68161,"kind":"person","name":"Snyder Douglas B.","position":1,"cik":"0001754125","reported_name":"Snyder Douglas B.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Share Options","published_at":"2021-03-02T21:42:29.000Z","date":"2021-03-01","kind":"exercise","acquired":false,"shares":6636,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F6","text":"Converted from British Pounds Sterling to U.S. Dollars using currency ratio of 1.00 British Pound Sterling = 1.39 U.S. Dollars as of March 1, 2021."},{"field":"kind","element":"transactionCoding","label":"F1","text":"Exercise of share options.  Following the exercise, these shares were converted into American Depositary Shares (\"ADS\") of the Issuer. Each ADS represents twelve ordinary shares of the Issuer."}],"balance_after":0,"derivative":{"exercise_price":0.0014,"exercise_date":"2021-03-01","expiration_date":"2021-03-01","underlying":"Ordinary Shares","underlying_shares":6636},"source":{"system":"sec-edgar","filing":"0000899243-21-009225","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1351288/000089924321009225/doc4.xml","form_type":"4"}},{"id":2819583,"issuer":{"id":139616,"kind":"organization","name":"GW PHARMACEUTICALS PLC","symbol":"GWPH"},"owners":[{"id":68161,"kind":"person","name":"Snyder Douglas B.","position":1,"cik":"0001754125","reported_name":"Snyder Douglas B.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Share Options","published_at":"2021-03-02T21:42:29.000Z","date":"2021-02-26","kind":"exercise","acquired":false,"shares":9612,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Converted from British Pounds Sterling to U.S. Dollars using currency ratio of 1.00 British Pound Sterling = 1.39 U.S. Dollars as of February 26, 2021."},{"field":"kind","element":"transactionCoding","label":"F1","text":"Exercise of share options.  Following the exercise, these shares were converted into American Depositary Shares (\"ADS\") of the Issuer. Each ADS represents twelve ordinary shares of the Issuer."}],"balance_after":0,"derivative":{"exercise_price":0.0014,"exercise_date":"2021-02-26","expiration_date":"2021-02-26","underlying":"Ordinary Shares","underlying_shares":9612},"source":{"system":"sec-edgar","filing":"0000899243-21-009225","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1351288/000089924321009225/doc4.xml","form_type":"4"}},{"id":2819582,"issuer":{"id":139616,"kind":"organization","name":"GW PHARMACEUTICALS PLC","symbol":"GWPH"},"owners":[{"id":68161,"kind":"person","name":"Snyder Douglas B.","position":1,"cik":"0001754125","reported_name":"Snyder Douglas B.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Share Options","published_at":"2021-03-02T21:42:29.000Z","date":"2021-02-26","kind":"exercise","acquired":false,"shares":128172,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Converted from British Pounds Sterling to U.S. Dollars using currency ratio of 1.00 British Pound Sterling = 1.39 U.S. Dollars as of February 26, 2021."},{"field":"kind","element":"transactionCoding","label":"F1","text":"Exercise of share options.  Following the exercise, these shares were converted into American Depositary Shares (\"ADS\") of the Issuer. Each ADS represents twelve ordinary shares of the Issuer."}],"balance_after":0,"derivative":{"exercise_price":0.0014,"exercise_date":"2021-02-26","expiration_date":"2021-02-26","underlying":"Ordinary Shares","underlying_shares":128172},"source":{"system":"sec-edgar","filing":"0000899243-21-009225","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1351288/000089924321009225/doc4.xml","form_type":"4"}},{"id":2819581,"issuer":{"id":139616,"kind":"organization","name":"GW PHARMACEUTICALS PLC","symbol":"GWPH"},"owners":[{"id":68161,"kind":"person","name":"Snyder Douglas B.","position":1,"cik":"0001754125","reported_name":"Snyder Douglas B.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Ordinary Shares","published_at":"2021-03-02T21:42:29.000Z","date":"2021-03-01","kind":"tax_withholding","acquired":false,"shares":3408,"price":17.85,"value":60832.8,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"Withhold to cover vested RSU style share options."},{"field":"shares","element":"transactionShares","label":"F4","text":"Represented by ADS."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported is price per ordinary share converted from price per ADS."}],"balance_after":70248,"source":{"system":"sec-edgar","filing":"0000899243-21-009225","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1351288/000089924321009225/doc4.xml","form_type":"4"}},{"id":2819580,"issuer":{"id":139616,"kind":"organization","name":"GW PHARMACEUTICALS PLC","symbol":"GWPH"},"owners":[{"id":68161,"kind":"person","name":"Snyder Douglas B.","position":1,"cik":"0001754125","reported_name":"Snyder Douglas B.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Ordinary Shares","published_at":"2021-03-02T21:42:29.000Z","date":"2021-03-01","kind":"exercise","acquired":true,"shares":6636,"price":0.0014,"value":9.2904,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Exercise of share options.  Following the exercise, these shares were converted into American Depositary Shares (\"ADS\") of the Issuer. Each ADS represents twelve ordinary shares of the Issuer."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Converted from British Pounds Sterling to U.S. Dollars using currency ratio of 1.00 British Pound Sterling = 1.39 U.S. Dollars as of February 26, 2021."}],"balance_after":73656,"source":{"system":"sec-edgar","filing":"0000899243-21-009225","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1351288/000089924321009225/doc4.xml","form_type":"4"}},{"id":2819579,"issuer":{"id":139616,"kind":"organization","name":"GW PHARMACEUTICALS PLC","symbol":"GWPH"},"owners":[{"id":68161,"kind":"person","name":"Snyder Douglas B.","position":1,"cik":"0001754125","reported_name":"Snyder Douglas B.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Ordinary Shares","published_at":"2021-03-02T21:42:29.000Z","date":"2021-02-26","kind":"tax_withholding","acquired":false,"shares":4937,"price":17.9,"value":88372.3,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"Withhold to cover vested RSU style share options."},{"field":"shares","element":"transactionShares","label":"F4","text":"Represented by ADS."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported is price per ordinary share converted from price per ADS."}],"balance_after":67020,"source":{"system":"sec-edgar","filing":"0000899243-21-009225","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1351288/000089924321009225/doc4.xml","form_type":"4"}},{"id":2819578,"issuer":{"id":139616,"kind":"organization","name":"GW PHARMACEUTICALS PLC","symbol":"GWPH"},"owners":[{"id":68161,"kind":"person","name":"Snyder Douglas B.","position":1,"cik":"0001754125","reported_name":"Snyder Douglas B.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Ordinary Shares","published_at":"2021-03-02T21:42:29.000Z","date":"2021-02-26","kind":"exercise","acquired":true,"shares":9612,"price":0.0014,"value":13.4568,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Exercise of share options.  Following the exercise, these shares were converted into American Depositary Shares (\"ADS\") of the Issuer. Each ADS represents twelve ordinary shares of the Issuer."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Converted from British Pounds Sterling to U.S. Dollars using currency ratio of 1.00 British Pound Sterling = 1.39 U.S. Dollars as of February 26, 2021."}],"balance_after":71957,"source":{"system":"sec-edgar","filing":"0000899243-21-009225","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1351288/000089924321009225/doc4.xml","form_type":"4"}},{"id":2819577,"issuer":{"id":139616,"kind":"organization","name":"GW PHARMACEUTICALS PLC","symbol":"GWPH"},"owners":[{"id":68161,"kind":"person","name":"Snyder Douglas B.","position":1,"cik":"0001754125","reported_name":"Snyder Douglas B.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Ordinary Shares","published_at":"2021-03-02T21:42:29.000Z","date":"2021-02-26","kind":"tax_withholding","acquired":false,"shares":65827,"price":17.9,"value":1178303.3,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"Withhold to cover vested RSU style share options."},{"field":"shares","element":"transactionShares","label":"F4","text":"Represented by ADS."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported is price per ordinary share converted from price per ADS."}],"balance_after":62345,"source":{"system":"sec-edgar","filing":"0000899243-21-009225","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1351288/000089924321009225/doc4.xml","form_type":"4"}},{"id":2819576,"issuer":{"id":139616,"kind":"organization","name":"GW PHARMACEUTICALS PLC","symbol":"GWPH"},"owners":[{"id":68161,"kind":"person","name":"Snyder Douglas B.","position":1,"cik":"0001754125","reported_name":"Snyder Douglas B.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Ordinary Shares","published_at":"2021-03-02T21:42:29.000Z","date":"2021-02-26","kind":"exercise","acquired":true,"shares":128172,"price":0.0014,"value":179.4408,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Exercise of share options.  Following the exercise, these shares were converted into American Depositary Shares (\"ADS\") of the Issuer. Each ADS represents twelve ordinary shares of the Issuer."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Converted from British Pounds Sterling to U.S. Dollars using currency ratio of 1.00 British Pound Sterling = 1.39 U.S. Dollars as of February 26, 2021."}],"balance_after":128172,"source":{"system":"sec-edgar","filing":"0000899243-21-009225","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1351288/000089924321009225/doc4.xml","form_type":"4"}},{"id":2835513,"issuer":{"id":139616,"kind":"organization","name":"GW PHARMACEUTICALS PLC","symbol":"GWPH"},"owners":[{"id":68161,"kind":"person","name":"Snyder Douglas B.","position":1,"cik":"0001754125","reported_name":"Snyder Douglas B.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Share Options","published_at":"2021-02-24T18:51:37.000Z","date":"2021-02-22","kind":"grant","acquired":true,"shares":72528,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F3","text":"Granted pursuant to the Issuer's Long-Term Incentive Plan."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Converted from British Pounds Sterling to U.S. Dollars using currency ratio of 1.00 British Pound Sterling = 1.41 U.S. Dollars as of February 22, 2021."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"These share options will vest in four equal annual installments beginning on February 22, 2022 and be automatically exercised upon vesting."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Subject to accelerated vesting in connection with the closing of the transactions contemplated by the Transaction Agreement, dated as of February 3, 2021, by and among Jazz Pharmaceuticals UK Holdings Limited, Jazz Pharmaceuticals Public Limited Company and GW Pharmaceuticals plc."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"These share options will vest in four equal annual installments beginning on February 22, 2022 and be automatically exercised upon vesting."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"Subject to accelerated vesting in connection with the closing of the transactions contemplated by the Transaction Agreement, dated as of February 3, 2021, by and among Jazz Pharmaceuticals UK Holdings Limited, Jazz Pharmaceuticals Public Limited Company and GW Pharmaceuticals plc."}],"balance_after":72528,"derivative":{"exercise_price":0.0014,"underlying":"Ordinary Shares","underlying_shares":72528},"source":{"system":"sec-edgar","filing":"0000899243-21-008097","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1351288/000089924321008097/doc4.xml","form_type":"4"}},{"id":2835512,"issuer":{"id":139616,"kind":"organization","name":"GW PHARMACEUTICALS PLC","symbol":"GWPH"},"owners":[{"id":68161,"kind":"person","name":"Snyder Douglas B.","position":1,"cik":"0001754125","reported_name":"Snyder Douglas B.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Share Options","published_at":"2021-02-24T18:51:37.000Z","date":"2021-02-22","kind":"grant","acquired":true,"shares":45324,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Granted pursuant to the Issuer's Long-Term Incentive Plan. These share options will vest and be automatically exercised on February 22, 2024 if certain performance conditions are satisfied."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Converted from British Pounds Sterling to U.S. Dollars using currency ratio of 1.00 British Pound Sterling = 1.41 U.S. Dollars as of February 22, 2021."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Granted pursuant to the Issuer's Long-Term Incentive Plan. These share options will vest and be automatically exercised on February 22, 2024 if certain performance conditions are satisfied."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Subject to accelerated vesting in connection with the closing of the transactions contemplated by the Transaction Agreement, dated as of February 3, 2021, by and among Jazz Pharmaceuticals UK Holdings Limited, Jazz Pharmaceuticals Public Limited Company and GW Pharmaceuticals plc."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Granted pursuant to the Issuer's Long-Term Incentive Plan. These share options will vest and be automatically exercised on February 22, 2024 if certain performance conditions are satisfied."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"Subject to accelerated vesting in connection with the closing of the transactions contemplated by the Transaction Agreement, dated as of February 3, 2021, by and among Jazz Pharmaceuticals UK Holdings Limited, Jazz Pharmaceuticals Public Limited Company and GW Pharmaceuticals plc."}],"balance_after":45324,"derivative":{"exercise_price":0.0014,"underlying":"Ordinary Shares","underlying_shares":45324},"source":{"system":"sec-edgar","filing":"0000899243-21-008097","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1351288/000089924321008097/doc4.xml","form_type":"4"}},{"id":2951586,"issuer":{"id":139616,"kind":"organization","name":"GW PHARMACEUTICALS PLC","symbol":"GWPH"},"owners":[{"id":68161,"kind":"person","name":"Snyder Douglas B.","position":1,"cik":"0001754125","reported_name":"Snyder Douglas B.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Ordinary Shares","published_at":"2020-12-09T20:00:09.000Z","date":"2020-12-07","kind":"sale","acquired":false,"shares":2400,"price":11.3,"value":27120.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale reported was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 6, 2020."},{"field":"shares","element":"transactionShares","label":"F2","text":"Following the exercise, these shares were converted into American Depositary Shares (\"ADS\") of the Issuer. Each ADS represents twelve ordinary shares of the Issuer."},{"field":"price","element":"transactionPricePerShare","label":"F8","text":"Converted from price per ADS. The price reported in Column 4 is a weighted average price per ordinary share ($135.6500 per ADS). These shares were sold in multiple transactions at prices ranging from $135.65 per ADS (or $11.30 per ordinary share) to $135.65 per ADS (or $11.30 per ordinary share), inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000899243-20-033216","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1351288/000089924320033216/doc4.xml","form_type":"4"}},{"id":2951585,"issuer":{"id":139616,"kind":"organization","name":"GW PHARMACEUTICALS PLC","symbol":"GWPH"},"owners":[{"id":68161,"kind":"person","name":"Snyder Douglas B.","position":1,"cik":"0001754125","reported_name":"Snyder Douglas B.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Ordinary Shares","published_at":"2020-12-09T20:00:09.000Z","date":"2020-12-07","kind":"sale","acquired":false,"shares":1200,"price":11.19,"value":13428.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale reported was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 6, 2020."},{"field":"shares","element":"transactionShares","label":"F2","text":"Following the exercise, these shares were converted into American Depositary Shares (\"ADS\") of the Issuer. Each ADS represents twelve ordinary shares of the Issuer."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"Converted from price per ADS. The price reported in Column 4 is a weighted average price per ordinary share ($134.3200 per ADS). These shares were sold in multiple transactions at prices ranging from $134.32 per ADS (or $11.19 per ordinary share) to $134.32 per ADS (or $11.19 per ordinary share), inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range."}],"balance_after":2400,"source":{"system":"sec-edgar","filing":"0000899243-20-033216","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1351288/000089924320033216/doc4.xml","form_type":"4"}},{"id":2951584,"issuer":{"id":139616,"kind":"organization","name":"GW PHARMACEUTICALS PLC","symbol":"GWPH"},"owners":[{"id":68161,"kind":"person","name":"Snyder Douglas B.","position":1,"cik":"0001754125","reported_name":"Snyder Douglas B.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Ordinary Shares","published_at":"2020-12-09T20:00:09.000Z","date":"2020-12-07","kind":"sale","acquired":false,"shares":5076,"price":11.11,"value":56394.36,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale reported was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 6, 2020."},{"field":"shares","element":"transactionShares","label":"F2","text":"Following the exercise, these shares were converted into American Depositary Shares (\"ADS\") of the Issuer. Each ADS represents twelve ordinary shares of the Issuer."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"Converted from price per ADS. The price reported in Column 4 is a weighted average price per ordinary share ($133.2948 per ADS). These shares were sold in multiple transactions at prices ranging from $132.90 per ADS (or $11.08 per ordinary share) to $133.64 per ADS (or $11.14 per ordinary share), inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range."}],"balance_after":3600,"source":{"system":"sec-edgar","filing":"0000899243-20-033216","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1351288/000089924320033216/doc4.xml","form_type":"4"}},{"id":2951583,"issuer":{"id":139616,"kind":"organization","name":"GW PHARMACEUTICALS PLC","symbol":"GWPH"},"owners":[{"id":68161,"kind":"person","name":"Snyder Douglas B.","position":1,"cik":"0001754125","reported_name":"Snyder Douglas B.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Ordinary Shares","published_at":"2020-12-09T20:00:09.000Z","date":"2020-12-07","kind":"sale","acquired":false,"shares":3984,"price":11.02,"value":43903.68,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale reported was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 6, 2020."},{"field":"shares","element":"transactionShares","label":"F2","text":"Following the exercise, these shares were converted into American Depositary Shares (\"ADS\") of the Issuer. Each ADS represents twelve ordinary shares of the Issuer."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Converted from price per ADS. The price reported in Column 4 is a weighted average price per ordinary share ($132.2066 per ADS). These shares were sold in multiple transactions at prices ranging from $131.87 per ADS (or $10.99 per ordinary share) to $132.30 per ADS (or $11.03 per ordinary share), inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range."}],"balance_after":8676,"source":{"system":"sec-edgar","filing":"0000899243-20-033216","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1351288/000089924320033216/doc4.xml","form_type":"4"}},{"id":2951582,"issuer":{"id":139616,"kind":"organization","name":"GW PHARMACEUTICALS PLC","symbol":"GWPH"},"owners":[{"id":68161,"kind":"person","name":"Snyder Douglas B.","position":1,"cik":"0001754125","reported_name":"Snyder Douglas B.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Ordinary Shares","published_at":"2020-12-09T20:00:09.000Z","date":"2020-12-07","kind":"sale","acquired":false,"shares":9444,"price":10.95,"value":103411.8,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale reported was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 6, 2020."},{"field":"shares","element":"transactionShares","label":"F2","text":"Following the exercise, these shares were converted into American Depositary Shares (\"ADS\") of the Issuer. Each ADS represents twelve ordinary shares of the Issuer."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Converted from price per ADS. The price reported in Column 4 is a weighted average price per ordinary share ($131.3749 per ADS). These shares were sold in multiple transactions at prices ranging from $130.83 per ADS (or $10.90 per ordinary share) to $131.81 per ADS (or $10.98 per ordinary share), inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range."}],"balance_after":23660,"source":{"system":"sec-edgar","filing":"0000899243-20-033216","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1351288/000089924320033216/doc4.xml","form_type":"4"}},{"id":2951581,"issuer":{"id":139616,"kind":"organization","name":"GW PHARMACEUTICALS PLC","symbol":"GWPH"},"owners":[{"id":68161,"kind":"person","name":"Snyder Douglas B.","position":1,"cik":"0001754125","reported_name":"Snyder Douglas B.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Ordinary Shares","published_at":"2020-12-09T20:00:09.000Z","date":"2020-12-07","kind":"sale","acquired":false,"shares":4800,"price":10.84,"value":52032.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale reported was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 6, 2020."},{"field":"shares","element":"transactionShares","label":"F2","text":"Following the exercise, these shares were converted into American Depositary Shares (\"ADS\") of the Issuer. Each ADS represents twelve ordinary shares of the Issuer."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Converted from price per ADS. The price reported in Column 4 is a weighted average price per ordinary share ($130.0325 per ADS). These shares were sold in multiple transactions at prices ranging from $129.69 per ADS (or $10.81 per ordinary share) to $130.50 per ADS (or $10.88 per ordinary share), inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range."}],"balance_after":22104,"source":{"system":"sec-edgar","filing":"0000899243-20-033216","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1351288/000089924320033216/doc4.xml","form_type":"4"}},{"id":3015914,"issuer":{"id":139616,"kind":"organization","name":"GW PHARMACEUTICALS PLC","symbol":"GWPH"},"owners":[{"id":68161,"kind":"person","name":"Snyder Douglas B.","position":1,"cik":"0001754125","reported_name":"Snyder Douglas B.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Ordinary Shares","published_at":"2020-10-02T16:40:49.000Z","date":"2020-09-30","kind":"sale","acquired":false,"shares":14400,"price":8.13,"value":117072.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale reported was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 13, 2020."},{"field":"shares","element":"transactionShares","label":"F2","text":"Represented by American Depositary Shares (\"ADS\") of the Issuer. Each ADS represents twelve ordinary shares of the Issuer."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported is price per ordinary share converted from price per ADS."}],"balance_after":26904,"source":{"system":"sec-edgar","filing":"0000899243-20-026863","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1351288/000089924320026863/doc4.xml","form_type":"4"}},{"id":3060015,"issuer":{"id":139616,"kind":"organization","name":"GW PHARMACEUTICALS PLC","symbol":"GWPH"},"owners":[{"id":68161,"kind":"person","name":"Snyder Douglas B.","position":1,"cik":"0001754125","reported_name":"Snyder Douglas B.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Stock Options","published_at":"2020-08-12T20:06:42.000Z","date":"2020-08-10","kind":"exercise","acquired":false,"shares":9180,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Converted from British Pounds Sterling to U.S. Dollars using currency ratio of 1.00 British Pound Sterling = 1.31 U.S. Dollars as of August 10, 2020."},{"field":"kind","element":"transactionCoding","label":"F1","text":"Exercise of stock options.  Following the exercise, these shares were converted into American Depositary Shares (\"ADS\") of the Issuer. Each ADS represents twelve ordinary shares of the Issuer."}],"balance_after":0,"derivative":{"exercise_price":0.0013,"exercise_date":"2020-08-10","expiration_date":"2020-08-10","underlying":"Ordinary Shares","underlying_shares":9180},"source":{"system":"sec-edgar","filing":"0000899243-20-022190","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1351288/000089924320022190/doc4.xml","form_type":"4"}},{"id":3060014,"issuer":{"id":139616,"kind":"organization","name":"GW PHARMACEUTICALS PLC","symbol":"GWPH"},"owners":[{"id":68161,"kind":"person","name":"Snyder Douglas B.","position":1,"cik":"0001754125","reported_name":"Snyder Douglas B.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Stock Options","published_at":"2020-08-12T20:06:42.000Z","date":"2020-08-10","kind":"exercise","acquired":false,"shares":122364,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Converted from British Pounds Sterling to U.S. Dollars using currency ratio of 1.00 British Pound Sterling = 1.31 U.S. Dollars as of August 10, 2020."},{"field":"kind","element":"transactionCoding","label":"F1","text":"Exercise of stock options.  Following the exercise, these shares were converted into American Depositary Shares (\"ADS\") of the Issuer. Each ADS represents twelve ordinary shares of the Issuer."}],"balance_after":0,"derivative":{"exercise_price":0.0013,"exercise_date":"2020-08-10","expiration_date":"2020-08-10","underlying":"Ordinary Shares","underlying_shares":122364},"source":{"system":"sec-edgar","filing":"0000899243-20-022190","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1351288/000089924320022190/doc4.xml","form_type":"4"}},{"id":3060013,"issuer":{"id":139616,"kind":"organization","name":"GW PHARMACEUTICALS PLC","symbol":"GWPH"},"owners":[{"id":68161,"kind":"person","name":"Snyder Douglas B.","position":1,"cik":"0001754125","reported_name":"Snyder Douglas B.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Ordinary Shares","published_at":"2020-08-12T20:06:42.000Z","date":"2020-08-11","kind":"sale","acquired":false,"shares":24000,"price":9.4,"value":225600.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F6","text":"The sale reported was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 5, 2020."},{"field":"shares","element":"transactionShares","label":"F4","text":"Represented by ADS."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported is price per ordinary share converted from price per ADS."}],"balance_after":41304,"source":{"system":"sec-edgar","filing":"0000899243-20-022190","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1351288/000089924320022190/doc4.xml","form_type":"4"}},{"id":3060012,"issuer":{"id":139616,"kind":"organization","name":"GW PHARMACEUTICALS PLC","symbol":"GWPH"},"owners":[{"id":68161,"kind":"person","name":"Snyder Douglas B.","position":1,"cik":"0001754125","reported_name":"Snyder Douglas B.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Ordinary Shares","published_at":"2020-08-12T20:06:42.000Z","date":"2020-08-10","kind":"tax_withholding","acquired":false,"shares":9180,"price":9.11,"value":83629.8,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"Withhold to cover vested RSU style share options."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported is price per ordinary share converted from price per ADS."}],"balance_after":65304,"source":{"system":"sec-edgar","filing":"0000899243-20-022190","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1351288/000089924320022190/doc4.xml","form_type":"4"}},{"id":3060011,"issuer":{"id":139616,"kind":"organization","name":"GW PHARMACEUTICALS PLC","symbol":"GWPH"},"owners":[{"id":68161,"kind":"person","name":"Snyder Douglas B.","position":1,"cik":"0001754125","reported_name":"Snyder Douglas B.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Ordinary Shares","published_at":"2020-08-12T20:06:42.000Z","date":"2020-08-10","kind":"exercise","acquired":true,"shares":9180,"price":0.0013,"value":11.934,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Exercise of stock options.  Following the exercise, these shares were converted into American Depositary Shares (\"ADS\") of the Issuer. Each ADS represents twelve ordinary shares of the Issuer."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Converted from British Pounds Sterling to U.S. Dollars using currency ratio of 1.00 British Pound Sterling = 1.31 U.S. Dollars as of August 10, 2020."}],"balance_after":74484,"source":{"system":"sec-edgar","filing":"0000899243-20-022190","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1351288/000089924320022190/doc4.xml","form_type":"4"}},{"id":3060010,"issuer":{"id":139616,"kind":"organization","name":"GW PHARMACEUTICALS PLC","symbol":"GWPH"},"owners":[{"id":68161,"kind":"person","name":"Snyder Douglas B.","position":1,"cik":"0001754125","reported_name":"Snyder Douglas B.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Ordinary Shares","published_at":"2020-08-12T20:06:42.000Z","date":"2020-08-10","kind":"tax_withholding","acquired":false,"shares":57060,"price":9.11,"value":519816.6,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"Withhold to cover vested RSU style share options."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported is price per ordinary share converted from price per ADS."}],"balance_after":65304,"source":{"system":"sec-edgar","filing":"0000899243-20-022190","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1351288/000089924320022190/doc4.xml","form_type":"4"}},{"id":3060009,"issuer":{"id":139616,"kind":"organization","name":"GW PHARMACEUTICALS PLC","symbol":"GWPH"},"owners":[{"id":68161,"kind":"person","name":"Snyder Douglas B.","position":1,"cik":"0001754125","reported_name":"Snyder Douglas B.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Ordinary Shares","published_at":"2020-08-12T20:06:42.000Z","date":"2020-08-10","kind":"exercise","acquired":true,"shares":122364,"price":0.0013,"value":159.0732,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Exercise of stock options.  Following the exercise, these shares were converted into American Depositary Shares (\"ADS\") of the Issuer. Each ADS represents twelve ordinary shares of the Issuer."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Converted from British Pounds Sterling to U.S. Dollars using currency ratio of 1.00 British Pound Sterling = 1.31 U.S. Dollars as of August 10, 2020."}],"balance_after":122364,"source":{"system":"sec-edgar","filing":"0000899243-20-022190","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1351288/000089924320022190/doc4.xml","form_type":"4"}},{"id":3086290,"issuer":{"id":139616,"kind":"organization","name":"GW PHARMACEUTICALS PLC","symbol":"GWPH"},"owners":[{"id":68161,"kind":"person","name":"Snyder Douglas B.","position":1,"cik":"0001754125","reported_name":"Snyder Douglas B.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Ordinary Shares","published_at":"2020-07-08T20:00:39.000Z","date":"2020-07-06","kind":"sale","acquired":false,"shares":9804,"price":10.5,"value":102942.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale reported was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 5, 2020."},{"field":"shares","element":"transactionShares","label":"F2","text":"Represented by American Depositary Shares of the Issuer (\"ADS\"). Each ADS represents twelve ordinary shares of the Issuer."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported is price per ordinary share converted from price per ADS."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F4","text":"Column 5 of Table I of the reporting person's Form 4 filed with the SEC on March 4, 2020 includes 57,492 ordinary shares underlying RSU style share options granted pursuant to the Issuer's Long-Term Incentive Plan, including (i) 19,908 ordinary shares vesting automatically in two equal installments on August 10, 2020 and 2021, (ii) 19,224 ordinary shares vesting automatically in two equal installments on February 26, 2021 and 2022, and (iii) 18,360 ordinary shares vesting automatically in three equal installments on March 1, 2021, 2022, and 2023. These ordinary shares have been excluded from Column 5 of this Form 4 and will be reported as each tranche is vested and automatically exercised."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000899243-20-018765","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1351288/000089924320018765/doc4.xml","form_type":"4"}},{"id":3118526,"issuer":{"id":139616,"kind":"organization","name":"GW PHARMACEUTICALS PLC","symbol":"GWPH"},"owners":[{"id":68161,"kind":"person","name":"Snyder Douglas B.","position":1,"cik":"0001754125","reported_name":"Snyder Douglas B.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Share Options","published_at":"2020-06-08T20:06:37.000Z","date":"2020-06-04","kind":"grant","acquired":true,"shares":89952,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F2","text":"Granted pursuant to the Issuer's Long-Term Incentive Plan."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Converted from British Pounds Sterling to U.S. Dollars using currency ratio of 1.00 British Pound Sterling = 1.26 U.S. Dollars as of June 4, 2020."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"These share options will vest in four equal annual installments beginning on June 4, 2021 and be automatically exercised upon vesting."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"These share options will vest in four equal annual installments beginning on June 4, 2021 and be automatically exercised upon vesting."}],"balance_after":89952,"derivative":{"exercise_price":0.0013,"underlying":"Ordinary Shares","underlying_shares":89952},"source":{"system":"sec-edgar","filing":"0000899243-20-015701","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1351288/000089924320015701/doc4.xml","form_type":"4"}},{"id":3118525,"issuer":{"id":139616,"kind":"organization","name":"GW PHARMACEUTICALS PLC","symbol":"GWPH"},"owners":[{"id":68161,"kind":"person","name":"Snyder Douglas B.","position":1,"cik":"0001754125","reported_name":"Snyder Douglas B.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Share Options","published_at":"2020-06-08T20:06:37.000Z","date":"2020-06-04","kind":"grant","acquired":true,"shares":149856,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Granted pursuant to the Issuer's Long-Term Incentive Plan. These share options will vest and be automatically exercised on June 4, 2023 if certain performance conditions are satisfied."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Converted from British Pounds Sterling to U.S. Dollars using currency ratio of 1.00 British Pound Sterling = 1.26 U.S. Dollars as of June 4, 2020."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Granted pursuant to the Issuer's Long-Term Incentive Plan. These share options will vest and be automatically exercised on June 4, 2023 if certain performance conditions are satisfied."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Granted pursuant to the Issuer's Long-Term Incentive Plan. These share options will vest and be automatically exercised on June 4, 2023 if certain performance conditions are satisfied."}],"balance_after":149856,"derivative":{"exercise_price":0.0013,"underlying":"Ordinary Shares","underlying_shares":149856},"source":{"system":"sec-edgar","filing":"0000899243-20-015701","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1351288/000089924320015701/doc4.xml","form_type":"4"}},{"id":3227105,"issuer":{"id":139616,"kind":"organization","name":"GW PHARMACEUTICALS PLC","symbol":"GWPH"},"owners":[{"id":68161,"kind":"person","name":"Snyder Douglas B.","position":1,"cik":"0001754125","reported_name":"Snyder Douglas B.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Ordinary Shares","published_at":"2020-03-04T18:03:54.000Z","date":"2020-03-02","kind":"sale","acquired":false,"shares":2568,"price":8.32,"value":21365.76,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Automatic sale to cover vested restricted stock units that have been previously reported in Column 5 of Table I."},{"field":"shares","element":"transactionShares","label":"F2","text":"Represented by American Depositary Shares of the Issuer (\"ADS\"). Each ADS represents twelve ordinary shares of the Issuer."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported is price per ordinary share converted from price per ADS."}],"balance_after":67296,"source":{"system":"sec-edgar","filing":"0000899243-20-006998","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1351288/000089924320006998/doc4.xml","form_type":"4"}},{"id":3241017,"issuer":{"id":139616,"kind":"organization","name":"GW PHARMACEUTICALS PLC","symbol":"GWPH"},"owners":[{"id":68161,"kind":"person","name":"Snyder Douglas B.","position":1,"cik":"0001754125","reported_name":"Snyder Douglas B.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Ordinary Shares","published_at":"2020-02-28T18:06:33.000Z","date":"2020-02-26","kind":"sale","acquired":false,"shares":240,"price":9.2,"value":2208.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Automatic sale of vested restricted stock units that have been previously reported in Column 5 of Table I."},{"field":"shares","element":"transactionShares","label":"F2","text":"Represented by American Depositary Shares of the Issuer (\"ADS\"). Each ADS represents twelve ordinary shares of the Issuer."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported is price per ordinary share converted from price per ADS."}],"balance_after":69864,"source":{"system":"sec-edgar","filing":"0000899243-20-006331","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1351288/000089924320006331/doc4.xml","form_type":"4"}},{"id":3241016,"issuer":{"id":139616,"kind":"organization","name":"GW PHARMACEUTICALS PLC","symbol":"GWPH"},"owners":[{"id":68161,"kind":"person","name":"Snyder Douglas B.","position":1,"cik":"0001754125","reported_name":"Snyder Douglas B.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Ordinary Shares","published_at":"2020-02-28T18:06:33.000Z","date":"2020-02-26","kind":"sale","acquired":false,"shares":3636,"price":9.17,"value":33342.12,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Automatic sale of vested restricted stock units that have been previously reported in Column 5 of Table I."},{"field":"shares","element":"transactionShares","label":"F2","text":"Represented by American Depositary Shares of the Issuer (\"ADS\"). Each ADS represents twelve ordinary shares of the Issuer."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported is price per ordinary share converted from price per ADS."}],"balance_after":70104,"source":{"system":"sec-edgar","filing":"0000899243-20-006331","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1351288/000089924320006331/doc4.xml","form_type":"4"}},{"id":3431967,"issuer":{"id":139616,"kind":"organization","name":"GW PHARMACEUTICALS PLC","symbol":"GWPH"},"owners":[{"id":68161,"kind":"person","name":"Snyder Douglas B.","position":1,"cik":"0001754125","reported_name":"Snyder Douglas B.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Ordinary Shares","published_at":"2019-08-21T17:30:39.000Z","date":"2019-08-19","kind":"sale","acquired":false,"shares":5424,"price":13.04,"value":70728.96,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 14, 2019."},{"field":"shares","element":"transactionShares","label":"F2","text":"Represented by American Depositary Shares of the Issuer (\"ADSs\"). Each ADS represents twelve ordinary shares of the Issuer."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a price per ordinary share converted from price per ADS."}],"balance_after":73740,"source":{"system":"sec-edgar","filing":"0000899243-19-022228","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1351288/000089924319022228/doc4.xml","form_type":"4"}},{"id":3438608,"issuer":{"id":139616,"kind":"organization","name":"GW PHARMACEUTICALS PLC","symbol":"GWPH"},"owners":[{"id":68161,"kind":"person","name":"Snyder Douglas B.","position":1,"cik":"0001754125","reported_name":"Snyder Douglas B.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Ordinary Shares","published_at":"2019-08-14T17:30:20.000Z","date":"2019-08-12","kind":"sale","acquired":false,"shares":3756,"price":13.88,"value":52133.28,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 14, 2019."},{"field":"shares","element":"transactionShares","label":"F2","text":"Represented by American Depositary Shares of the Issuer (\"ADSs\"). Each ADS represents twelve ordinary shares of the Issuer."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a price per ordinary share converted from price per ADS."}],"balance_after":79164,"source":{"system":"sec-edgar","filing":"0000899243-19-021736","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1351288/000089924319021736/doc4.xml","form_type":"4"}},{"id":3463658,"issuer":{"id":139616,"kind":"organization","name":"GW PHARMACEUTICALS PLC","symbol":"GWPH"},"owners":[{"id":68161,"kind":"person","name":"Snyder Douglas B.","position":1,"cik":"0001754125","reported_name":"Snyder Douglas B.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Ordinary Shares","published_at":"2019-07-11T21:00:24.000Z","date":"2019-07-09","kind":"sale","acquired":false,"shares":4968,"price":14.42,"value":71638.56,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported were effected pursuant to a Rule 10b-5 trading plan adopted by the Reporting Person on May 14, 2019."},{"field":"shares","element":"transactionShares","label":"F2","text":"Represented by American Depositary Shares of the Issuer (\"ADSs\"). Each ADS represents twelve ordinary shares of the Issuer."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a price per ordinary share converted from price per ADS."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F4","text":"Includes 56,376 and 26,544 ordinary shares underlying restricted stock units previously reported as stock options on the reporting person's Form 3 filed on October 1, 2018 and Form 4 filed on March 5, 2019, respectively."}],"balance_after":82920,"source":{"system":"sec-edgar","filing":"0000899243-19-019500","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1351288/000089924319019500/doc4.xml","form_type":"4"}},{"id":3611713,"issuer":{"id":139616,"kind":"organization","name":"GW PHARMACEUTICALS PLC","symbol":"GWPH"},"owners":[{"id":68161,"kind":"person","name":"Snyder Douglas B.","position":1,"cik":"0001754125","reported_name":"Snyder Douglas B.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Stock Options","published_at":"2019-03-05T21:08:42.000Z","date":"2019-03-01","kind":"grant","acquired":true,"shares":6636,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Granted pursuant to the Issuer's Long-Term Incentive Plan."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"Converted from British Pounds Sterling to U.S. Dollars using currency ratio of 1.00 British Pound Sterling = 1.32 U.S. Dollars as of March 1, 2019."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"These stock options will vest automatically on exercisable date."}],"balance_after":6636,"derivative":{"exercise_price":0.0013,"exercise_date":"2023-03-01","underlying":"Ordinary Shares","underlying_shares":6636},"source":{"system":"sec-edgar","filing":"0000899243-19-006339","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1351288/000089924319006339/doc4.xml","form_type":"4"}},{"id":3611712,"issuer":{"id":139616,"kind":"organization","name":"GW PHARMACEUTICALS PLC","symbol":"GWPH"},"owners":[{"id":68161,"kind":"person","name":"Snyder Douglas B.","position":1,"cik":"0001754125","reported_name":"Snyder Douglas B.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Stock Options","published_at":"2019-03-05T21:08:42.000Z","date":"2019-03-01","kind":"grant","acquired":true,"shares":6636,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Granted pursuant to the Issuer's Long-Term Incentive Plan."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"Converted from British Pounds Sterling to U.S. Dollars using currency ratio of 1.00 British Pound Sterling = 1.32 U.S. Dollars as of March 1, 2019."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"These stock options will vest automatically on exercisable date."}],"balance_after":6636,"derivative":{"exercise_price":0.0013,"exercise_date":"2022-03-01","underlying":"Ordinary Shares","underlying_shares":6636},"source":{"system":"sec-edgar","filing":"0000899243-19-006339","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1351288/000089924319006339/doc4.xml","form_type":"4"}},{"id":3611711,"issuer":{"id":139616,"kind":"organization","name":"GW PHARMACEUTICALS PLC","symbol":"GWPH"},"owners":[{"id":68161,"kind":"person","name":"Snyder Douglas B.","position":1,"cik":"0001754125","reported_name":"Snyder Douglas B.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Stock Options","published_at":"2019-03-05T21:08:42.000Z","date":"2019-03-01","kind":"grant","acquired":true,"shares":6636,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Granted pursuant to the Issuer's Long-Term Incentive Plan."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"Converted from British Pounds Sterling to U.S. Dollars using currency ratio of 1.00 British Pound Sterling = 1.32 U.S. Dollars as of March 1, 2019."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"These stock options will vest automatically on exercisable date."}],"balance_after":6636,"derivative":{"exercise_price":0.0013,"exercise_date":"2021-03-01","underlying":"Ordinary Shares","underlying_shares":6636},"source":{"system":"sec-edgar","filing":"0000899243-19-006339","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1351288/000089924319006339/doc4.xml","form_type":"4"}},{"id":3611710,"issuer":{"id":139616,"kind":"organization","name":"GW PHARMACEUTICALS PLC","symbol":"GWPH"},"owners":[{"id":68161,"kind":"person","name":"Snyder Douglas B.","position":1,"cik":"0001754125","reported_name":"Snyder Douglas B.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Stock Options","published_at":"2019-03-05T21:08:42.000Z","date":"2019-03-01","kind":"grant","acquired":true,"shares":6636,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Granted pursuant to the Issuer's Long-Term Incentive Plan."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"Converted from British Pounds Sterling to U.S. Dollars using currency ratio of 1.00 British Pound Sterling = 1.32 U.S. Dollars as of March 1, 2019."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"These stock options will vest automatically on exercisable date."}],"balance_after":6636,"derivative":{"exercise_price":0.0013,"exercise_date":"2020-03-01","underlying":"Ordinary Shares","underlying_shares":6636},"source":{"system":"sec-edgar","filing":"0000899243-19-006339","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1351288/000089924319006339/doc4.xml","form_type":"4"}},{"id":3611709,"issuer":{"id":139616,"kind":"organization","name":"GW PHARMACEUTICALS PLC","symbol":"GWPH"},"owners":[{"id":68161,"kind":"person","name":"Snyder Douglas B.","position":1,"cik":"0001754125","reported_name":"Snyder Douglas B.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Stock Options","published_at":"2019-03-05T21:08:42.000Z","date":"2019-03-01","kind":"grant","acquired":true,"shares":88524,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Granted pursuant to the Issuer's Long-Term Incentive Plan."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"Converted from British Pounds Sterling to U.S. Dollars using currency ratio of 1.00 British Pound Sterling = 1.32 U.S. Dollars as of March 1, 2019."}],"balance_after":88524,"derivative":{"exercise_price":0.0013,"exercise_date":"2022-03-01","expiration_date":"2023-03-15","underlying":"Ordinary Shares","underlying_shares":88524},"source":{"system":"sec-edgar","filing":"0000899243-19-006339","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1351288/000089924319006339/doc4.xml","form_type":"4"}},{"id":3611708,"issuer":{"id":139616,"kind":"organization","name":"GW PHARMACEUTICALS PLC","symbol":"GWPH"},"owners":[{"id":68161,"kind":"person","name":"Snyder Douglas B.","position":1,"cik":"0001754125","reported_name":"Snyder Douglas B.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Stock Options","published_at":"2019-03-05T21:08:42.000Z","date":"2019-03-01","kind":"grant","acquired":true,"shares":46644,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Granted pursuant to the Issuer's Long-Term Incentive Plan."},{"field":"security","element":"securityTitle","label":"F2","text":"The reported options are options to purchase American Depositary Shares of the Issuer (\"ADS\"). Each ADS represents twelve ordinary shares of the Issuer."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"The exercise price reported is price per ordinary share converted from price per ADS ($172.01)."}],"balance_after":46644,"derivative":{"exercise_price":14.33,"exercise_date":"2022-03-01","expiration_date":"2029-03-01","underlying":"Ordinary Shares","underlying_shares":46644},"source":{"system":"sec-edgar","filing":"0000899243-19-006339","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1351288/000089924319006339/doc4.xml","form_type":"4"}},{"id":3626030,"issuer":{"id":139616,"kind":"organization","name":"GW PHARMACEUTICALS PLC","symbol":"GWPH"},"owners":[{"id":68161,"kind":"person","name":"Snyder Douglas B.","position":1,"cik":"0001754125","reported_name":"Snyder Douglas B.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Stock Options","published_at":"2019-02-28T17:00:26.000Z","date":"2019-02-26","kind":"exercise","acquired":false,"shares":9612,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Converted from British Pounds Sterling to U.S. Dollars using currency ratio of 1.00 British Pound Sterling = 1.29 U.S. Dollars as of February 26, 2019."}],"balance_after":0,"derivative":{"exercise_price":0.0013,"exercise_date":"2019-02-26","expiration_date":"2020-03-15","underlying":"Ordinary Shares","underlying_shares":9612},"source":{"system":"sec-edgar","filing":"0000899243-19-005256","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1351288/000089924319005256/doc4.xml","form_type":"4"}},{"id":3626029,"issuer":{"id":139616,"kind":"organization","name":"GW PHARMACEUTICALS PLC","symbol":"GWPH"},"owners":[{"id":68161,"kind":"person","name":"Snyder Douglas B.","position":1,"cik":"0001754125","reported_name":"Snyder Douglas B.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Ordinary Shares","published_at":"2019-02-28T17:00:26.000Z","date":"2019-02-26","kind":"sale","acquired":false,"shares":48,"price":12.37,"value":593.76,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"These ordinary shares are represented by ADSs."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported is price per ordinary share converted from price per ADS."}],"balance_after":4968,"source":{"system":"sec-edgar","filing":"0000899243-19-005256","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1351288/000089924319005256/doc4.xml","form_type":"4"}},{"id":3626028,"issuer":{"id":139616,"kind":"organization","name":"GW PHARMACEUTICALS PLC","symbol":"GWPH"},"owners":[{"id":68161,"kind":"person","name":"Snyder Douglas B.","position":1,"cik":"0001754125","reported_name":"Snyder Douglas B.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Ordinary Shares","published_at":"2019-02-28T17:00:26.000Z","date":"2019-02-26","kind":"sale","acquired":false,"shares":420,"price":12.44,"value":5224.8,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"These ordinary shares are represented by ADSs."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported is price per ordinary share converted from price per ADS."}],"balance_after":5016,"source":{"system":"sec-edgar","filing":"0000899243-19-005256","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1351288/000089924319005256/doc4.xml","form_type":"4"}},{"id":3626027,"issuer":{"id":139616,"kind":"organization","name":"GW PHARMACEUTICALS PLC","symbol":"GWPH"},"owners":[{"id":68161,"kind":"person","name":"Snyder Douglas B.","position":1,"cik":"0001754125","reported_name":"Snyder Douglas B.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Ordinary Shares","published_at":"2019-02-28T17:00:26.000Z","date":"2019-02-26","kind":"sale","acquired":false,"shares":1200,"price":12.44,"value":14928.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"These ordinary shares are represented by ADSs."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported is price per ordinary share converted from price per ADS."}],"balance_after":5436,"source":{"system":"sec-edgar","filing":"0000899243-19-005256","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1351288/000089924319005256/doc4.xml","form_type":"4"}},{"id":3626026,"issuer":{"id":139616,"kind":"organization","name":"GW PHARMACEUTICALS PLC","symbol":"GWPH"},"owners":[{"id":68161,"kind":"person","name":"Snyder Douglas B.","position":1,"cik":"0001754125","reported_name":"Snyder Douglas B.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Ordinary Shares","published_at":"2019-02-28T17:00:26.000Z","date":"2019-02-26","kind":"sale","acquired":false,"shares":2400,"price":12.42,"value":29808.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"These ordinary shares are represented by ADSs."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported is price per ordinary share converted from price per ADS."}],"balance_after":6636,"source":{"system":"sec-edgar","filing":"0000899243-19-005256","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1351288/000089924319005256/doc4.xml","form_type":"4"}},{"id":3626025,"issuer":{"id":139616,"kind":"organization","name":"GW PHARMACEUTICALS PLC","symbol":"GWPH"},"owners":[{"id":68161,"kind":"person","name":"Snyder Douglas B.","position":1,"cik":"0001754125","reported_name":"Snyder Douglas B.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Ordinary Shares","published_at":"2019-02-28T17:00:26.000Z","date":"2019-02-26","kind":"sale","acquired":false,"shares":576,"price":12.41,"value":7148.16,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"These ordinary shares are represented by ADSs."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported is price per ordinary share converted from price per ADS."}],"balance_after":9036,"source":{"system":"sec-edgar","filing":"0000899243-19-005256","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1351288/000089924319005256/doc4.xml","form_type":"4"}},{"id":3626024,"issuer":{"id":139616,"kind":"organization","name":"GW PHARMACEUTICALS PLC","symbol":"GWPH"},"owners":[{"id":68161,"kind":"person","name":"Snyder Douglas B.","position":1,"cik":"0001754125","reported_name":"Snyder Douglas B.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Ordinary Shares","published_at":"2019-02-28T17:00:26.000Z","date":"2019-02-26","kind":"exercise","acquired":true,"shares":9612,"price":0.0013,"value":12.4956,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Exercise of stock options. Following the exercise, these shares were converted into 801 American Depositary Shares of the Issuer (\"ADS\"). Each ADS represents twelve ordinary shares of the Issuer."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Converted from British Pounds Sterling to U.S. Dollars using currency ratio of 1.00 British Pound Sterling = 1.29 U.S. Dollars as of February 26, 2019."}],"balance_after":9612,"source":{"system":"sec-edgar","filing":"0000899243-19-005256","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1351288/000089924319005256/doc4.xml","form_type":"4"}}]}